Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.76 |
| ▸ | TAS2R38 | P59533 | 3/20 | 0.76 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.76 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.76 |
| ▸ | GAA | P10253 | 7/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.70 |
| ▸ | MEN1 | O00255 | 3/20 | 0.70 |
| ▸ | RAB9A | P51151 | 2/20 | 0.70 |
| ▸ | NOX1 | Q9Y5S8 | 2/20 | 0.70 |
| ▸ | NPC1 | O15118 | 1/20 | 0.70 |
| ▸ | MAOA | P21397 | 3/20 | 0.65 |
| ▸ | MAOB | P27338 | 3/20 | 0.65 |
| ▸ | MAPT | P10636 | 3/20 | 0.65 |
| ▸ | LMNA | P02545 | 2/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.59 |
| ▸ | TP53 | P04637 | 1/20 | 0.56 |
| ▸ | TYR | P14679 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23324998 | 0.89 | ALDH1A1 (0.68) | ALDH1A1TAS2R38HSD17B10CYP3A4GAA | |
| SCHEMBL132620 | 0.87 | ALDH1A1 (1.00) | ALDH1A1TAS2R38HSD17B10CYP3A4GAA | |
| SCHEMBL9470190 | 0.84 | ALDH1A1 (0.94) | ALDH1A1TAS2R38HSD17B10CYP3A4GAA | |
| SCHEMBL8956322 | 0.84 | ALDH1A1 (0.94) | ALDH1A1TAS2R38HSD17B10CYP3A4GAA | |
| SCHEMBL730314 | 0.82 | ALDH1A1 (0.80) | ALDH1A1TAS2R38HSD17B10CYP3A4GAA | |
| Thiourea SCHEMBL21055683 | 0.80 | ALDH1A1 (0.85) | ALDH1A1TAS2R38HSD17B10CYP3A4GAA | |
| SCHEMBL5137359 | 0.79 | ALDH1A1 (1.00) | ALDH1A1TAS2R38HSD17B10CYP3A4GAA | |
| SCHEMBL9243020 | 0.78 | ALDH1A1 (0.81) | ALDH1A1TAS2R38HSD17B10CYP3A4GAA | |
| SCHEMBL23812525 | 0.78 | GAA (0.84) | ALDH1A1TAS2R38HSD17B10CYP3A4GAA | |
| SCHEMBL13694679 | 0.78 | ALDH1A1 (0.73) | ALDH1A1TAS2R38HSD17B10CYP3A4GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250100980-A1 | NOVEL LEUKOTRIENE B4 RECEPTOR INHIBITORS AND USE THEREOF | EWHA UNIVERSITY - INDUSTRY COLLABORATION FOUNDATION (KR) | 2025-03-27 | — | — | US | claimed |
| WO-2023121022-A1 | NOVEL LEUKOTRIENE B4 RECEPTOR INHIBITORS AND USE THEREOF | 이화여자대학교 산학협력단 | 2023-06-29 | — | — | WO | claimed |
| CN-116180169-A | Electronic plating additive composition and application thereof in inhibiting silver-ferrite interface nickel transverse electrodeposition | 厦门大学 | 2023-05-30 | — | — | CN | claimed |
| US-20170100352-A1 | Methods for treating or preventing neuroinflammation or autoimmune diseases | ELFORD HOWARD L (US) | 2017-04-13 | — | — | US | claimed |
| EP-2030615-A2 | Ribonucleotide reductase inhibitors for use in the treatment or prevention of neuroinflammatory or autoimmune diseases | ELFORD, Howard L. (US) | 2009-03-04 | — | — | EP | claimed |
| US-20090047250-A1 | Methods for treating or preventing neuroinflammation or autoimmune diseases | ELFORD HOWARD L | 2009-02-19 | — | — | US | claimed |
| US-20250100980-A1 | NOVEL LEUKOTRIENE B4 RECEPTOR INHIBITORS AND USE THEREOF | EWHA UNIVERSITY - INDUSTRY COLLABORATION FOUNDATION (KR) | 2025-03-27 | — | — | US | disclosed |
| US-20230293524-A1 | OTIC FORMULATIONS FOR DRUG-INDUCED OTOTOXICITY | SPIRAL THERAPEUTICS INC. | 2023-09-21 | — | — | US | disclosed |
| WO-2023121022-A1 | NOVEL LEUKOTRIENE B4 RECEPTOR INHIBITORS AND USE THEREOF | 이화여자대학교 산학협력단 | 2023-06-29 | — | — | WO | disclosed |
| CN-116180169-A | Electronic plating additive composition and application thereof in inhibiting silver-ferrite interface nickel transverse electrodeposition | 厦门大学 | 2023-05-30 | — | — | CN | disclosed |
| US-11234914-B2 | Monosubstituted urea derivatives as a self-tanning substance | MERCK PATENT GMBH (DE) | 2022-02-01 | — | — | US | disclosed |
| US-20200038304-A1 | MONOSUBSTITUTED UREA DERIVATIVES AS A SELF-TANNING SUBSTANCE | MERCK PATENT GMBH (DE) | 2020-02-06 | — | — | US | disclosed |
| US-20190142940-A1 | Method and system for effecting changes in pigmented tissue | MOAZED KAMBIZ THOMAS (US) | 2019-05-16 | — | — | US | disclosed |
| CN-102070556-A | 5-benzyl-4-alkyl-2-aminothiazole as well as preparation and application of 5-benzyl-4-alkyl-2-aminothiazole | UNIV HUNAN | 2011-05-25 | — | — | CN | disclosed |
| CN-102010406-A | 4-(benzofuran-5-yl)-2-aromatic aminothiazole and preparation method and application thereof | UNIV HUNAN | 2011-04-13 | — | — | CN | disclosed |
| WO-2011011065-A1 | METHOD AND SYSTEM FOR EFFECTING CHANGES IN PIGMENTED TISSUE | MOAZED KAMBIZ THOMAS (US) | 2011-01-27 | — | — | WO | disclosed |
| WO-2010087983-A1 | METHOD AND SYSTEM FOR EFFECTING CHANGES IN PIGMENTED TISSUE | MOAZED KAMBIZ THOMAS (US) | 2010-08-05 | — | — | WO | disclosed |
| EP-2030615-A2 | Ribonucleotide reductase inhibitors for use in the treatment or prevention of neuroinflammatory or autoimmune diseases | ELFORD, Howard L. (US) | 2009-03-04 | — | — | EP | disclosed |
| US-20090047250-A1 | Methods for treating or preventing neuroinflammation or autoimmune diseases | ELFORD HOWARD L | 2009-02-19 | — | — | US | disclosed |
| CN-1337961-A | Heteroaryl amidines, methyl amidiues and guanidines as protease inhibitors | DIMENSIONAL PHARM INC (US) | 2002-02-27 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250100980-A1 | NOVEL LEUKOTRIENE B4 RECEPTOR INHIBITORS AND USE THEREOF | LTB4R2, LTB4R, CYSLTR2 | ALDH1A1 2694/4885TAS2R38 1165/4885HSD17B10 1482/4885 |
| US-11234914-B2 | Monosubstituted urea derivatives as a self-tanning substance | SLC14A1, TYR, UROD | ALDH1A1 422/4885TAS2R38 1259/4885HSD17B10 1598/4885 |
| US-20090047250-A1 | Methods for treating or preventing neuroinflammation or autoimmune diseases | RNASE1, RNASEH1, TXNRD3 | ALDH1A1 1031/4885TAS2R38 4058/4885HSD17B10 1470/4885 |
| US-20170100352-A1 | Methods for treating or preventing neuroinflammation or autoimmune diseases | RNASE1, RNASEH1, TXNRD3 | ALDH1A1 1031/4885TAS2R38 4058/4885HSD17B10 1470/4885 |
| US-20200038304-A1 | MONOSUBSTITUTED UREA DERIVATIVES AS A SELF-TANNING SUBSTANCE | SLC14A1, TYR, UROD | ALDH1A1 422/4885TAS2R38 1259/4885HSD17B10 1598/4885 |
| US-20230293524-A1 | OTIC FORMULATIONS FOR DRUG-INDUCED OTOTOXICITY | OTC, SLC26A4, OAT | ALDH1A1 121/4885TAS2R38 795/4885HSD17B10 2300/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.